Compare Atmos Energy Corporation (ATO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Atmos Energy Corporation trades at $168.76 (market cap $28.38B), while Regeneron Pharmaceuticals Inc trades at $796.32 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.9× Atmos Energy Corporation's market cap, and Atmos Energy Corporation pays the higher dividend (2.38%). Which is the better fit depends on your goals.
| ATO | REGN | |
|---|---|---|
Market Cap | $28.38B | $83.19B |
Sector | Utilities | Health |
52-Week High | $192.25 | $812.27 |
52-Week Low | $162.44 | $545.94 |
Enterprise Value | $38.18B | $77.90B |
Dividend Yield | 2.38% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $170.19, down 1.04% today, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $1.43, beating expectations by 5.9%, and maintains strong fundamentals with 28.5% net income margin and $4.70B revenue. Recent board appointments and dividend declarations highlight corporate stability, while analyst consensus targets $190.57 with 45% buy ratings.
ATO presents a mixed outlook with solid earnings growth and dividend stability offset by bearish technical indicators and negative cash flow trends. The stock offers value through consistent profitability and infrastructure investments, though investors face risks from high capital expenditures and debt levels that could pressure future returns.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
